Novel Nucleoside Transport Inhibitors of Natural Origin

  • Yong-Su Zhen
  • Jian Su
  • Yu-Chuan Xue
  • Chang-Qing Qi
  • Ji-Lan Hu
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 370)


The salvage pathway of nucleotide biosynthesis is one of the attractive targets for cancer chemotherapy. Dipyridamole, a nucleoside transport inhibitor, may be used for blocking the salvage pathways. Studies have demonstrated that dipyridamole can reduce the rescue effect of exogenous nucleosides and potentiated the cytotoxicity of acivicin, an antimetabolite of de novo pathways of nucleotide biosynthesis, in hepatoma cells1, 2. The inhibitory effect of dipyridamole was cell growth phase -dependent. Cultured hepatoma cells in lag and log phase were highly sensitive to dipyridamole; by contrast, cells in stationary phase were insensitive3, 4. The combination of acivicn and dipyridamole administered in rats bearing s.c. transplanted hepatoma yielded a summation effect, decreasing NTP and dNTP pools5. The synergistic effect of dipyridamole and acivicin was also demonstrated in colon cancer cells6. There have been reports that dipyridamole potentiated the cytotoxicity of several antimetabolites including methotrexate, 5-fluorouracil and N-phosphonacetyl-L-aspartate (PALA)7, 8, 9. In addition to potentiating antimetabolites, dipyridamole was found to enhance the cytotoxicity of doxorubicin, etoposide, vincristine and mitoxantrone10, 11, 12. These synergistic effects of dipyridamole and drugs which are not antimetabolites were due to, at least in part, increased intracellular concentrations of anticancer drugs. Drug sensitivity of multidrug resistant cells may be modulated by dipyridamole13. The use of dipyridamole in cancer chemotherapy has drawn much attention and clinical trials have been underway14, 15. The study of dipyridamole indicates that blocking nucleoside salvage pathways by inhibition of nucleoside transport may be one of the effective ways in chemotherapy. By examination of a series of compounds of natural origin, we have found that green tea polyphenols (GP), antibiotics C3368-A (CA) and C3368-B (CB) are highly active in blocking nucleoside transport in cancer cells. Investigations have demonstrated that GP, CA or CB show synergistic effects with anticancer drugs.


Human Colon Cancer Cell Salvage Pathway Nucleoside Transport Growth Inhibition Assay Rescue Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    G. Weber, Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture, Cancer Res 43:3466 (1983).PubMedGoogle Scholar
  2. 2.
    Y.-S. Zhen, M.S. Lui and G. Weber, Effects of acivicin d dipyridamole on hepatoma 3924A cells, Cancer Res. 43:1616 (1983).PubMedGoogle Scholar
  3. 3.
    Y.-S. Zhen, M.A. Reardon and G. Weber, Amphotericin B renders stationary phase hepatoma cells sensitive to dipyridamole, Biochem. Biophys. Commun. 140:434 (1986).CrossRefGoogle Scholar
  4. 4.
    Y.-S. Zhen, M.A. Reardon and G. Weber, Amphotericin B: a biological response modifier in targeting against the salvage pathways, Biochem. Pharmacol. 36:3641 (1987).PubMedCrossRefGoogle Scholar
  5. 5.
    G. Weber, M.S. Lui, Y. Natsumeda and M.A. Faderan, Salvage capacity of hepatoma 3924A and action of dipyridamole, Advan. Enzyme Regul. 21:53069 (1983).Google Scholar
  6. 6.
    P.H. Fischer, R. Pamukcu, G. Bittner and J.K.V. Willson, Enhancement of the sensitivity of human colon cancer cells to growth inhibition by acivicin achieved through inhibition of nucleic acid precursor salvage by dipyridamole, Cancer Res. 44:3355 (1984).PubMedGoogle Scholar
  7. 7.
    J.A. Nelson and S. Drake, Potentiation of methotrexate toxicity by dipyridamole, Cancer Res. 44:2493 (1984).PubMedGoogle Scholar
  8. 8.
    J.L. Grem and P.H. Fischer, Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole, Cancer Res. 45:2967 (1985).PubMedGoogle Scholar
  9. 9.
    T.C.K. Chan and S.B. Howell, Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian cell line, Cancer Res. 45:3598 (1985).PubMedGoogle Scholar
  10. 10.
    H. Kusumoto, Y. Maehara, H. Anai, T. Kusumoto and K. Sugimachi, Potentiation of adriamycin cytotoxicity by dipyridamole against HeLa cells in vitro and sarcoma 180 cells in vivo, Cancer Res. 48:1208 (1988).PubMedGoogle Scholar
  11. 11.
    S.B. Howell, D. Horn, R. Sanga, J.S. Vick and I.S. Abramson, Comparison of the synergistic potentiation of etoposide, doxorubicin, and vincristine cytotoxicity by dipyridamole, Cancer Res, 49:3178 (1989).PubMedGoogle Scholar
  12. 12.
    M. Sotomatsu, S. Yugami, T. Shitara and T. Kuroume, Dipyridamole enhancement of drug sensitivity in acute lymphoblastic leukemia cells, Am. J. Hematol. 43:251 (1993).PubMedCrossRefGoogle Scholar
  13. 13.
    D.R. Shalinsky, M. Andreef and S.B. Howell, Modulation of drug sensitivity by dipyridamole in multidrug resistant tumor cells in vitro, Cancer Res. 50:7537 (1990).PubMedGoogle Scholar
  14. 14.
    J.K.V. Willson, P.H. Fischer, S.C. Remick, K.D. Tutsch, J.L. Grem, L. Nieting, J. Bruggink, J.M. Koeller and D.L. Trump, Methotrexate and dipyridamole combination therapy based upon inhibition of nucleoside salvage in humans, Cancer Res, 49:1866 (1989).PubMedGoogle Scholar
  15. 15.
    S.C. Remick, J.L. Grem, P.H. Fischer, K.D. Tutsch, D.B. Alberti, L.M. Nieting, M.B. Tombes, J. Bruggink and J.K.V. Willson, Phase I trial of 5-fluorouracil and dipyridamole administered by 72 h concurrent continuous infusion, Cancer Res, 50:2667 (1990).PubMedGoogle Scholar
  16. 16.
    Y.S. Zhen, S.S. Cao, T.C. Xue and S.Y. Wu, Green tea extract inhibits nucleoside transport and potentiates the antitumor effect of antimetabolites, Chin. Med. Sci. J. 6:1 (1991).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Yong-Su Zhen
    • 1
  • Jian Su
    • 1
  • Yu-Chuan Xue
    • 1
  • Chang-Qing Qi
    • 1
  • Ji-Lan Hu
    • 1
  1. 1.Institute of Medicinal BiotechnologyChinese Academy of Medical SciencesBeijingChina

Personalised recommendations